In line / mixed
Official results showed Q4 core growth of 1%, adjusted EPS of $2.14 and strong cash generation; full-year core revenue declined 1.5%.
[AS-EXP-002]Danaher
Q4 / FY2024: A better fourth quarter closed a down year, but the initial 2025 plan embedded a soft first quarter and only modest full-year recovery.
ResultIn line / mixedGuidanceMixed / newly framedEnvironmentmixed
Investment snapshot
What happened and why it mattered
Mixed / newly framed
Danaher guided to roughly 3% 2025 core growth after a low-single-digit Q1 decline, leaving the recovery weighted to later quarters.
[AS-EXP-002]Mixed cadence
Danaher guided to roughly 3% 2025 core growth after a low-single-digit Q1 decline, leaving the recovery weighted to later quarters.
[AS-EXP-002]Qualitative
The market welcomed the cleaner exit rate but remained sensitive to the back-end-loaded recovery and bioprocessing conversion.
[AS-ME-058]Results versus expectations
The print and the three most important read-throughs
Official results showed Q4 core growth of 1%, adjusted EPS of $2.14 and strong cash generation; full-year core revenue declined 1.5%.
- 1
Official results showed Q4 core growth of 1%, adjusted EPS of $2.14 and strong cash generation; full-year core revenue declined 1.5%.
Guidance bridge
GuidanceMixed / newly framedLatest outlook and KPI implications
Danaher guided to roughly 3% 2025 core growth after a low-single-digit Q1 decline, leaving the recovery weighted to later quarters.
| Metric | Prior | Latest | Consensus | Delta | Status | Reason / implication |
|---|---|---|---|---|---|---|
| FY2026 core revenue growth | +3% to +6% (initial framework) | +3% to +6% | +3.6% (Visible Alpha) | Confirmed | Updated | Continued recovery in end markets |
| FY2026 core growth (consensus ref.) | — | +3% to +6% | +3.6% VA / ~3.4% FactSet | In line | In line | Guide "in line with mid-term outlook and pre-result consensus" |
| Q1 2026 core revenue growth | Not previously guided | +Low-single digit | NOT AVAILABLE | New | New | Q1 conditions largely consistent with Q4 2025 |
| FY2026 adjusted EPS | Not formally guided (HSD growth implied) | $8.35 – $8.50 | $8.46 | New / +8% YoY at midpoint | New | Operating leverage plus 2025 cost actions |
| FY2026 adjusted EPS (consensus) | — | $8.35 – $8.50 | $8.42 VA / $8.41 FactSet | Broadly in line | In line | Includes $250M cost-saving benefit |
| Q1 2026 adj. operating margin | Not previously guided | ~28.5% | NOT AVAILABLE | New | New | Productivity carryover |
Management signal — paraphrased
Danaher guided to roughly 3% 2025 core growth after a low-single-digit Q1 decline, leaving the recovery weighted to later quarters.
Implied cadence
Danaher guided to roughly 3% 2025 core growth after a low-single-digit Q1 decline, leaving the recovery weighted to later quarters.
Stock reaction
Why the shares moved
The market welcomed the cleaner exit rate but remained sensitive to the back-end-loaded recovery and bioprocessing conversion.
- The market welcomed the cleaner exit rate but remained sensitive to the back-end-loaded recovery and bioprocessing conversion.
Did the reaction persist?
[AS-ME-058]Not independently calculated in the compact record.
Adjusted-close reaction
Independent return windows were not embedded in this compact record. The reaction assessment is qualitative.
Source-reported qualitative reaction; no independent price series embeddedMarket environment delta
EnvironmentmixedWhat management said about the operating backdrop
A better fourth quarter closed a down year, but the initial 2025 plan embedded a soft first quarter and only modest full-year recovery.
- Customer demand (pharma / A&G)Improving
Q4: momentum improving; pharma recovering modestly, A&G still constrained but comping easier
OutlookPharma to keep improving in 2026; A&G remains the swing factorKPI implicationSupports Life Sciences flat-to-modest recoveryManagement interpretation · Medium confidence · AS-ME-058 - Volumes / orders (bioprocessing)Improving
Q4: third consecutive quarter of sequential equipment order growth; consumables book-to-bill ~1x, equipment returned to revenue growth
OutlookHSD bioprocessing growth in 2026; one quarter "not yet a trend"KPI implicationBook-to-bill ~1x underpins HSD consumables into 2026Disclosed fact · High confidence · AS-ME-058 - Regional / end-market (China)Improving
Q4: China core down only LSD; bioprocessing returning to growth; VBP expected to moderate through 2026
OutlookChina a 2026 growth contributor in bioprocessing; VBP largely lappedKPI implicationReduces the drag on group core growthManagement interpretation · Medium confidence · [128]
- Channel / inventoryStable
Consumables lead times much shorter, so a book-to-bill of ~1x is "exactly where it needs to be"
OutlookNormalized consumables ordering cadenceKPI implicationReduces order-timing volatility riskManagement interpretation · Medium confidence · AS-ME-058 - Supply availability / reshoringImproving
Q4: reshoring conversations advancing; funnel concentrated on short-cycle brownfield, greenfield still incremental upside
OutlookMulti-year capex cycle; upside not yet in guideKPI implicationPotential upside to flat-equipment assumptionManagement interpretation · Medium confidence · AS-ME-058 - Input costs / capacity / utilizationImproving
Q4: industry utilization rates improved on 24 months of under-investment in new capacity, supporting future equipment demand
OutlookHigher utilization should pull forward capacity expansionKPI implicationSupports equipment order recovery thesisManagement interpretation · Medium confidence · [127]
- Competition (bioprocessing share)Stable
Management characterized perceived share shifts as "largely noise," saying share is stable and it hasn't heard of being spec'd out of processes
OutlookExpects to hold downstream share; refresh of bioreactors underwayKPI implicationProtects ~$6B bioprocessing revenue baseManagement interpretation · Medium confidence · [126] - PricingNO MATERIAL CHANGE
No material price change flagged in Q4; margin drag was cost-timing, not pricing
OutlookPricing not called out as a 2026 leverKPI implicationNeutral to marginsDisclosed fact · Medium confidence · AS-ME-058
Evidence and confidence
Source map
The AlphaSense report analyzed Q4/FY2025 despite a Q4/FY2024 prompt. Period-specific conclusions are reconstructed from Danaher's official 29 January 2025 release and adjacent-quarter evidence; the contaminated report is excluded from those claims.
AlphaSense synthesis
Open source ↗Official company source
Open source ↗AlphaSense market-environment synthesis
Open source ↗